Literature DB >> 23296108

Colorectal cancer in 2012: Revisiting landmark trials and identifying new therapies.

Christina Wu1, Richard M Goldberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23296108     DOI： 10.1038/nrclinonc.2012.227

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.

Authors:  Hanna K Sanoff; William R Carpenter; Til Stürmer; Richard M Goldberg; Christopher F Martin; Jason P Fine; Nadine Jackson McCleary; Jeffrey A Meyerhardt; Joyce Niland; Katherine L Kahn; Maria J Schymura; Deborah Schrag
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

3.  Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.

Authors:  Christophe Tournigand; Thierry André; Franck Bonnetain; Benoist Chibaudel; Gérard Lledo; Tamas Hickish; Josep Tabernero; Corrado Boni; Jean-Baptiste Bachet; Luis Teixeira; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

4.  Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.

Authors:  George A Poultsides; Elliot L Servais; Leonard B Saltz; Sujata Patil; Nancy E Kemeny; Jose G Guillem; Martin Weiser; Larissa K F Temple; W Douglas Wong; Phillip B Paty
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

5.  Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.

Authors:  Laurence E McCahill; Greg Yothers; Saima Sharif; Nicholas J Petrelli; Lily Lau Lai; Naftali Bechar; Jeffrey K Giguere; Shaker R Dakhil; Louis Fehrenbacher; Samia H Lopa; Lawrence D Wagman; Michael J O'Connell; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

6.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

7.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Authors:  Eric Van Cutsem; Josep Tabernero; Radek Lakomy; Hans Prenen; Jana Prausová; Teresa Macarulla; Paul Ruff; Guy A van Hazel; Vladimir Moiseyenko; David Ferry; Joe McKendrick; Jonathan Polikoff; Alexia Tellier; Rémi Castan; Carmen Allegra
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

8.  Comprehensive molecular characterization of human colon and rectal cancer.

Authors: 
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962

9.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Authors:  John Burn; Anne-Marie Gerdes; Finlay Macrae; Jukka-Pekka Mecklin; Gabriela Moeslein; Sylviane Olschwang; Diane Eccles; D Gareth Evans; Eamonn R Maher; Lucio Bertario; Marie-Luise Bisgaard; Malcolm G Dunlop; Judy W C Ho; Shirley V Hodgson; Annika Lindblom; Jan Lubinski; Patrick J Morrison; Victoria Murday; Raj Ramesar; Lucy Side; Rodney J Scott; Huw J W Thomas; Hans F Vasen; Gail Barker; Gillian Crawford; Faye Elliott; Mohammad Movahedi; Kirsi Pylvanainen; Juul T Wijnen; Riccardo Fodde; Henry T Lynch; John C Mathers; D Timothy Bishop
Journal:  Lancet       Date:  2011-10-27       Impact factor: 79.321
  9 in total
  2 in total

1.  Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.

Authors:  Johanna C Bendell; Heinz-Josef Lenz; Theresa Ryan; Bassel F El-Rayes; John L Marshall; Manuel R Modiano; Lowell L Hart; Clint D Kingsley; Thomas J George; Daisuke Nakashima; Jordan D Berlin
Journal:  Invest New Drugs       Date:  2014-04-03       Impact factor: 3.850

2.  Publishing Environmental Assessment and Management Science: Crossing the Hurdles.

Authors:  Rebecca A Efroymson; Mark J Peterson
Journal:  Bioscience       Date:  2020-09-30       Impact factor: 8.589
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.